Category: Clinical Trial Update Region: North America · United States Company: Bayer Corporation United States

Bayer initiates OASIS 4 phase III study of elinzanetant in breast cancer patients with vasomotor symptoms caused by endocrine therapy

By, Admin 1 min read
Share
Bayer initiates OASIS 4 phase III study of elinzanetant in breast cancer patients with vasomotor symptoms caused by endocrine therapy
Bayer, a global leader in women

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!